Bayer AG can expect a slowdown in the growth in sales of its blood loss drug Trasylol, after an independent study showed that the drug was associated with health risks, board member Wolfgang Plischke said after the full-year results news conference
March 6, 2006 14:10

Bayer AG can expect a slowdown in the growth in sales of its blood loss drug Trasylol, after an independent study showed that the drug was associated with health risks, board member Wolfgang Plischke said after the full-year results news conference.An independent... (Read Article)

Thirteen years ago, the FDA approved Trasylol (aprotinin) for use in patients undergoing heart bypass surgery. In January 2006, doctors, consumer advocates and a medical research group called for the removal of the drug from the market after a study found it... (Read Article)

Heart bypass surgery is performed to redirect blood around clogged arteries to increase blood flow and oxygen to the heart. A patient may undergo one, two, three or more bypasses depending on how many arteries are blocked. It is the most commonly performed major surgery in the US, with approximately 500,000 procedures conducted each year, according to Coronary Artery Bypass Graft Surgery at Heart Center Online. The FDA approved Trasylol in 1993 to control bleeding in patients undergoing heart surgery by blocking enzymes that dissolve blood clots. Although it was only approved for heart surgery, the drug has been administered off-label to patients undergoing other types of surgery. (Read Article)

Trasylol is a drug that is used to prevent blood loss in patients who have had various types of cardiac procedures such as cardiac bypass surgery and coronary artery bypass graft surgery (CABG). Unfortunately, many have had complications from this drug, which... (Read Article)

NEW YORK, January 31, 2006 --- Parker & Waichman, LLP (www.yourlawyer.com) announces that in addition to numerous inquiries from potential clients it has been retained in a case involving the use of Trasylol and is actively evaluating claims concerning Trasylol,... (Read Article)